Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Voxilaprevir in Hepatic Impairment
NCT02397707Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2015
- Primary completion
- Mar 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 1, open-label trial of voxilaprevir in hepatitis C (HCV) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Area under the concentration-time curve from time zero to the last quantifiable concentration, Area under the concentration-time curve from time zero to infinity and 1 more. Started Mar 2015; status: completed.
02
Drugs
voxilaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02397707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02397707.